What happened
In the twilight hours of Q3 2025, an unassuming document filed with the Securities and Exchange Commission (SEC) revealed a quiet yet potent storm stirring in the world of patient investment. Patient Capital Management, LLC, a fund known for its measured approach, has increased its position in Precigen by 10.2 million shares. The transaction, which unfolded at a valuation of $28.78 million based on the average closing price of that quarter, raises the fund’s stake to a formidable 26.5 million shares – an investment now worth $87.06 million.
The Undercurrents of Change
Trade direction: buy; position now represents 3.48% of the reported 13F assets under management. The long-term gambler watches, as the markets unfold like the slow march of time itself, witnessing new twists as old stakes are gradually raised.
To put the breadth of this investment in context, let’s look at the other prominent holdings that Patient Capital carries within its portfolio:
- GOOGL (NASDAQ): $149.10 million (6.0% of AUM)
- C (NYSE): $133.01 million (5.3% of AUM)
- UNH (NYSE): $128.23 million (5.1% of AUM)
- QXO (NYSE): $124.60 million (5.0% of AUM)
- AMZN (NASDAQ): $123.39 million (4.9% of AUM)
On the last trading day of October 29, 2025, shares of Precigen were valued at $4.01 – a 375.91% surge over the preceding year. This meteoric rise places the company far ahead of the S&P 500, outperforming the index by 356.34 percentage points.
The Landscape of the Market
| Metric | Value |
|---|---|
| Price (as of market close October 29, 2025) | $4.01 |
| Market Capitalization | $1.19 billion |
| Revenue (TTM) | $4.34 million |
| Net Income (TTM) | ($124.50 million) |
Where Science Meets Investment
Precigen, like a sculptor wielding tools of unseen precision, is crafting a new era in gene and cellular therapies. Their focus on disease-modifying therapeutics, paired with proprietary platforms like UltraVector, Sleeping Beauty, UltraCAR-T, and AdenoVerse Immunotherapy, marks their ambition to reshape the landscape of biotechnology. It is a race against time, where scientific prowess and investment converge to cure what afflicts humanity.
Precigen’s portfolio is not just a collection of inventions; it’s a declaration of intention. By securing collaborations with pharmaceutical companies, healthcare providers, and research organizations, they have positioned themselves as vanguards in the fight against cancer and other diseases that defy our understanding.
In a world teetering on the brink of breakthroughs, Precigen’s strategies align like the gears of a clock, ticking forward with intent. The company’s strength lies in its proprietary platforms, which promise to lead the way in developing life-altering treatments.
The Foolish Take
Though Precigen has not claimed a place among Patient Capital’s top five holdings, its role within the fund is undeniable. At 3.5% of the portfolio, it has quietly grown in importance. What once held a mere 1% of the portfolio at the close of Q2 2025 has now emerged as a significant stake.
The bet on Precigen, viewed through the lens of a seasoned investor, appears to be a wager that has paid off handsomely. Since June 30, 2025, the stock has soared by 191.5%, peaking in early September. The catalyst? The FDA’s full approval of Papzimeos, a drug designed to treat recurrent respiratory papillomatosis (RRP), a rare but devastating disease.
While the drug’s addressable population is limited, it holds a particular promise – a light in the darkness for those suffering from a condition once thought incurable. And with the arrival of treatment options, new patients may surface, desperate for any semblance of relief from their afflictions.
Glossary
13F assets under management: The value of securities reported by institutional investors in quarterly SEC Form 13F filings, offering a glimpse into their investment strategies.
AUM (Assets Under Management): The total market value of investments held on behalf of clients by a fund, representing the breadth of its influence.
Position: The amount of a specific security or asset held by an investor, a reflection of their belief in the company’s future.
Stake: The ownership interest or shares held by an investor, which may shift with time like the seasons.
Trade direction: A sign of intent – whether an investor is increasing their holdings or withdrawing, a subtle shift in strategy.
Outperforming: Achieving returns that surpass the benchmarks, a triumph over the forces that would seek to restrain progress.
Proprietary platforms: Technologies developed in-house, shielded from competitors, their value only growing with time.
Gene and cellular therapies: Treatments that manipulate the very essence of life – genes and cells – to fight diseases at their root.
Disease-modifying therapeutics: Medicines that do more than mask symptoms; they challenge the very core of diseases, altering their course.
Strategic collaborations: Partnerships formed not out of convenience, but out of necessity – two forces aligning to tackle shared goals.
TTM: The trailing twelve months, a measure of a company’s recent financial performance.
UltraCAR-T: A platform at the cutting edge of cancer therapy, where science and hope intersect.
📈
Read More
- The Unexpected Triumph of Novo Nordisk: A Dividend Hunter’s Delight
- Gold Rate Forecast
- General Hospital Recap, July 23 Episode: Drew Suspects Willow of Stalking Daisy
- XRP On The Brink: Are We About To Witness Crypto Fireworks Or Just Another Fizzle? 🎭
- Superman Lore Changed Forever? YOU WON’T BELIEVE WHAT HAPPENS!
- Bitcoin’s Paradox: Billionaire Buys, Price Stagnates
- Brent Oil Forecast
- AI Investing Through Dan Ives’ Lens: A Revolutionary ETF
- Tokenized Shares: Crypto’s Mirage of Innovation
- Big Sell on Big Data: When Even the Suits Say ‘Enough’s Enough’
2025-11-01 19:48